At PHC Holdings group, we are entering an immensely exciting time for our business. Our ambition is to become a more global diversified healthcare company, which we will achieve by growing our existing business segments and identifying new ways to expand our products and services. We believe that this will enable us to successfully contribute to the wellbeing of society and build a future of better healthcare for people across the world.

The journey for PHC Holdings group started in 2014, when our business carved out from Panasonic group. In 2016 we acquired the diabetes care business from Bayer and established Ascensia Diabetes Care, and we continued our transformation in April 2018, when we changed our name from Panasonic Healthcare Holdings Co., Ltd. to PHC Holdings Corporation. We are now about to enter the next transformative phase in the development of our business.

We currently offer value-added products and services through three core businesses: Medical Devices, Healthcare IT, and Life Sciences. With our signing of the agreement to acquire the Anatomical Pathology business from Thermo Fisher that was announced in January 2019, we are expanding our portfolio by adding a new and highly successful area of business that is showing considerable growth.

By working together with all stakeholders, we aim to continue to deliver new value to our customers and contribute to the wellbeing of society. We appreciate all of your support for the PHC Holdings group and look forward to working together to build a future of better healthcare.